General Atlantic L.P. Takes Position in Nurix Therapeutics, Inc. $NRIX

General Atlantic L.P. purchased a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 4,897,159 shares of the company’s stock, valued at approximately $92,899,000. Nurix Therapeutics accounts for about 3.2% of General Atlantic L.P.’s holdings, making the stock its 9th largest position.

Several other large investors have also recently bought and sold shares of NRIX. Larson Financial Group LLC raised its position in Nurix Therapeutics by 339.0% during the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after buying an additional 1,190 shares during the period. Intesa Sanpaolo Wealth Management acquired a new position in Nurix Therapeutics in the 4th quarter worth about $31,000. Caitong International Asset Management Co. Ltd acquired a new position in Nurix Therapeutics in the 4th quarter worth about $33,000. Wexford Capital LP acquired a new position in Nurix Therapeutics in the 3rd quarter worth about $41,000. Finally, Tower Research Capital LLC TRC increased its position in Nurix Therapeutics by 118.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock worth $73,000 after purchasing an additional 3,475 shares during the last quarter.

Insider Transactions at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 14,055 shares of the stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total transaction of $233,313.00. Following the transaction, the chief financial officer owned 37,592 shares of the company’s stock, valued at approximately $624,027.20. This represents a 27.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 3,214 shares of the stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $16.65, for a total value of $53,513.10. Following the transaction, the insider directly owned 120,399 shares in the company, valued at approximately $2,004,643.35. This represents a 2.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 19,657 shares of company stock worth $326,586. 6.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

NRIX has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Tuesday, April 21st. Wells Fargo & Company lowered Nurix Therapeutics from an “overweight” rating to a “hold” rating and dropped their target price for the stock from $28.00 to $25.00 in a research report on Monday, June 8th. Truist Financial upped their target price on Nurix Therapeutics from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $34.00 target price on shares of Nurix Therapeutics in a research report on Monday. Finally, Jefferies Financial Group upped their target price on Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.14.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX opened at $17.07 on Wednesday. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of -5.40 and a beta of 1.86. The business’s 50-day simple moving average is $16.48 and its 200-day simple moving average is $16.91. Nurix Therapeutics, Inc. has a 52 week low of $8.19 and a 52 week high of $22.50.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). The company had revenue of $6.25 million for the quarter, compared to analyst estimates of $14.25 million. Nurix Therapeutics had a negative net margin of 411.37% and a negative return on equity of 64.21%. As a group, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.88 earnings per share for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.